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Abstract-The presence of a betaz-adrenergic receptor in the epidermis has been demonstrated, based 
on the following pieces of information: (I) the addition of salbutamol, a betas-agonist, to slices of 
epidermal tissue increased the levels of cyclic AMP in the tissue above control levels in a dose-dependent 
manner with a maximum response after 5 min of incubation in 5 x lo-’ M salbutamol, (2) the addition 
of butoxamine, a betas-antagonist, in conjunction with isoproterenol or salbutamol reduced the epidermal 
cyclic AMP levels when compared to levels obtained with agonist alone, (3) practolol, a betal-antagonist. 
had little effect on the salbutamol-induced increases in the cyclic AMP levels and further elevated the 
levels of cyclic AMP obtained by the addition of isoproterenol, (4) the addition of propranolol to the 
tissue in conjunction with isoproterenol or salbutamol reduced the levels of cyclic AMP to near control 
values, and (5) Ro 20-1724, a cyclic nucleotide phosphodiesterase inhibitor, maintained the salbutamol- 
elevated cyclic AMP levels for a longer period of time. 
Cyclic AMP has been implicated as an important 
modulator or control component in cellular prolifer- 
ation [l, 21 and/or differentiation [3, 41 in a number 
of systems. The epidermis appears to be a suitable 
system for investigating the possible regulatory role 
for this compound since the epidermis is a tissue 
undergoing constant renewal wherein the cells nor- 
mally progress through a differentiative process 
before sloughing into the environment. The presence 
of a beta-adrenergic responsive system in the epi- 
dermis has been established 12, 5, 61. Since beta- 
adrenergic receptors have been subdivided further 
into PI and Pz, based on the response elicited from 
a series of sympathomimetic amines with respect to 
cardiac stimulation or bronchodilation and vaso- 
pressor activities [7], the further establishing of the 
/31 or p2 nature of the receptors in the epidermis was 
of interest from a scientific as well as a practical 
point of view. If cyclic AMP does have an important 
role in the control of proliferation or differentiation 
in the epidermis, then the type of receptor present 
in the epidermis would be important from the point 
of view of treating skin disease. It would seem to be 
advantageous to the patient to be able to alter the 
cyclic AMP levels in the epidermis with minimal 
involvement of cardiac function. Therefore, a /31 and 
@agonist, isoproterenol (IPR) [7]. a /3z-agonist, sal- 
butamol [8, 91, a PI and &-antagonist, propranolol 
[lo], a PI-antagonist, practolol [ll]. and a &antag- 
onist, butoxamine [lO-121, were utilized in an 
attempt to delineate the nature of the receptor pres- 
ent in the epidermal tissue. 
MATERIALS AND METHODS 
Hairless mice (HRS/J) were obtained from Jack- 
son Laboratories (Bar Harbor, ME), the Castroviejo 
* Part of this work has been presented in abstract form 
at the Federation of American Societies for Experimental 
Biology in April, 1977. 
keratome from the Storz Instrument Co. (St. Louis, 
MO), and isoproterenol, norepinephrine and pro- 
pranolol from the Sigma Chemical Co. (St. Louis, 
MO). The following compounds were received as 
gifts: butoxamine from the Burroughs Wellcome Co. 
(Triangle Park, NC), papaverine hydrochloride from 
Eli Lilly & Co. (Indianapolis, IN), practolol from 
Ayerst Laboratories Inc. (New York, NY), QH-25B 
from Pharmacia As (Hillerod, Denmark), Ro 20- 
1724 from Hoffmann-LaRoche Inc. (Nutley. NJ), 
and salbutamol (albuterol) from the Schering Co. 
(Kenilworth, NJ). 
Young adult male mice were killed by cervical 
dislocation, and epidermal strips were immediately 
removed with a Castroviejo keratome, adjusted to 
a depth of 0.1 mm. These epidermal strips were cut 
into small pieces and placed in beakers containing 
a Krebs-Ringer bicarbonate solution with added 
glucose. One mouse yields approximately 6(?-80 mg 
wet weight of epidermis, which is sufficient material 
for at least one time point. 
Slices were preincubated for 20 min at 37” in a 
shaking water bath. At zero time the test compounds 
were added to the experimental beakers and buffer 
was added to the control beakers. At the designated 
time points, tissue samples were removed and 
immediately placed in liquid nitrogen. The samples 
were weighed, pulverized under liquid nitrogen. and 
homogenized in 6% trichloroacetic acid containing 
tracer amounts of tritiated adenosine 3’S’-cyclic 
monophosphate ([3H]-cyclic AMP). The homogen- 
ates were centrifuged at 18,000 g for 20 min at 4”. 
The supernatant fractions containing cyclic AMP 
were extracted three times with 6 vol. of water- 
saturated ethyl ether. The pellets from the centrifu- 
gation step were saved for the DNA determination 
[13], using salmon sperm DNA as the standard, and 
for the protein determination [14], using crystalline 
bovine serum albumin as the standard. 
The cyclic AMP present in the ether-extracted 
supernatant fractions was partially purified by col- 
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Fig. I. Salbutamol-induced increases in cyclic AMP levels 
in incubated mouse epidermal slices. Keratomed mouse 
epidermal slices were preincubated for 20 min at 37” prior 
to drug addition. Tissue aliquots were removed at the time 
points indicated and immediately frozen in liquid nitrogen. 
Methods for cyclic AMP determination are given in 
Materials and Methods. The numbers in parentheses indi- 
cate the number of individual experiments represented at 
each data point. 
umn chromatography of Bio-Rad AG l-X2 resin in 
the chloride form. After application of the samples, 
the columns were washed with water, followed by 
elution of the cyclic AMP from the resin with a 
solution of 0.01 N HCI. The fractions containing the 
cyclic AMP were lyophilized, and subsequently the 
samples were resuspended in sodium acetate buffer, 
pH 4.4. An aliquot of the resuspended samples was 
counted to determine the percentage of the cyclic 
AMP recovered for assay. The amount of cyclic 
AMP in the samples was determined by the protein 
binding method 1151 with each sample assayed in 
duplicate at three dilutions. 
The human biopsy samples were obtained with a 
keratome setting of 0.1 mm from uninvolved areas 
and 0.25 to 0.45 mm for areas with lesions. The areas 
to be keratomed were infiltrated with 1% lidocaine 
without epinephrine just prior to the removal of the 
epidermis. All other procedures were identical to 
those listed for mouse tissue. 
RESULTS 
The curves shown in Fig. 1 indicate the levels of 
cyclic AMP obtained in the epidermal slices in 
response to increased concentrations of salbutamol 
in comparison to control samples after 5 and 10min 
of incubation. The maximum accumulation of cyclic 
AMP (3.8-fold increase) occurred at a concentration 
of approximately 5 x 1 OF5 M salbutamol after 5 min 
of incubation, with a slightly lower accumulation 
(3-fold increase) after 10 min of incubation in 10m4 
M salbutamol. The absence of a cyclic nucleotide 
phosphodiesterase (PDE) inhibitor in the experi- 
ment may account for the decrease in cyclic AMP 
levels after 10 min of incubation in comparison to 
the levels of cyclic AMP after 5 min of incubation. 
In data not shown, the antagonists (practolol, pro- 
pranolol or butoxamine) have no significant effect 
on the basal level of 6.9 i 1.1 pmoles cyclic AMPimg 
of protein present in the epidermal slices after 5 or 
10 min of incubation. The effects of adding each of 
these antagonists to the epidermal slices in conjunc- 
tion with salbutamo1 are demonstrated in Table 1. 
The addition of 5 X lop5 M salbutamol to the slices 
resulted in a 3.8-fold increase in the cyclic AMP 
levels; this increase was reduced to control levels by 
the addition of lo-” or 10m4 M propranolol to the 
tissue just prior to the addition of salbutamol. 
The results obtained by incubating the epidermal 
slices with a betai-antagonist practolol. in addition 
to the agonist salbutamoi, are given in Table I. The 
addition of lo-’ M practolol to the epidermal slices, 
in addition to salbutamol, resulted in a slight (12 per 
cent) decrease in the cyclic AMP levels in comparison 
to the values obtained in the presence of salbutamol 
alone. At a IO-fold higher concentration of practolol, 
a 49 per cent decrease in the amount of cyclic AMP 
accumulation occurred in comparison to saibutamol 
alone after 5 min of incubation. The increased accu- 
mulation of cyclic AMP in the epidermal slices after 
5 min of incubation with salbutamol was decreased 
60 per cent by the addition of lo- M butoxamine 
to the tissue. A lo-fold increase in the concentration 
of this antagonist resulted in a slight but significant 
Table 1. Effects of propranolol, butoxamine and practolol 




Additions p value* N 
None 
5 x lo-’ M Salbutamoi 
5 x IO-' M SaIbutamol 
+ 
1 x 10V5 M Propranolol 
5 x 10e5 M Salbutamol 
+ 
1 x 10m4 M Propranolol 
5 x 10m5 M Salbutamol 
+ 
1 x lo-’ M Butoxamine 
5 x 10e5 M Salbutamol 
7.5 5 0.4 8 
28.1 ?I 7.1 0.02 1 x 
7.1 t 0.4 0.010 7 
9.3 t 0.9 0.015 7 
12.9 t 1.2 0.023 6 
11.6 i: 0.9 0.022 6 
1 x 10T4 M Butoxamine 
5 x lo-’ M Salbutamol 
+ 
1 x IO-’ M Practolol 
5 x 10m5 M Salbutamol 
+ 
1 x 10m4 M Practolol 
24.8 + 6.5 0.445 7 
14.4 ? 3.2 0.296 7 
* Epidermal tissue slices were preincubated for 20 min 
at 37” in buffer. The antagonists and salhutamol were added 
simultaneously at zero time. 
‘r Data are expressed as the mean it: standard error of 
the mean. 
$ The P value for salbutamol alone is m comparison to 
control. All other P values compare the salbutamol plus 
antagonist to salbutamol alone. Because of the interrelated 
nature of the three tests, a multiple comparison procedure 
should be employed. Using an overall a-level of 0.1. the 
three treatment comparisons are significant 
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Table 2. Effects of a cyclic nucleotide phosphodiesterase 
inhibitor in the presence of salbutamol on cyclic AMP 




None 10.4 rt 2.5 
5 x 1O-4 Ro 20-1724 17.6 rt 2.8 
5 x 10W5 M Salbutamol 24.1 t 2.7 
5 X lo-’ M Salbutamol 
f 
5 x 1O-.4 M Ro 20-1724 
74.8 ZiZ 9.3 
* Epidermal tissue slices were preincubated for 20 min 
in buffer at 37”. At zero time Ro 20-1724 and/or salbutamol 
were added to the various beakers containing tissue. After 
5 min of incubation the tissue slices were removed and 
immediately frozen in liquid nitrogen. 
t Data are expressed as the mean * standard error of 
the mean; N = three experiments. 
additional decrease in the cyclic AMP levels. Similar 
results were observed after 10 min of incubation. 
In an attempt to obtain further information con- 
cerning the effectiveness of the betas-agonist sal- 
butamol, the PDE inhibitor Ro 20-1724 was added 
to the incubation mixture in addition to the agonist. 
The addition of Ro 20-1724 (10V5 to 5 X low4 M) to 
the epidermal tissue slices resulted in a maximum 
increase of 84 per cent in the cyclic AMP levels 
above control values after 5 min of incubation (data 
not shown). As shown in Table 2, salbutamol 
increased the cyclic AMP levels 2.3-fold above con- 
trol levels after 5 min of incubation. The addition of 
the PDE inhibitor and the agonist resulted in a 
synergistic 7.2-fold increase in the cyclic AMP levels. 
The results obtained with the addition of the beta1 
and betaz-agonist (IPR) to the epidermal tissue slices 
are given in Table 3. The samples were also treated 
Table 3. Effects of butoxamine and practolol on cyclic 
AMP levels elevated by a 81 and &-agonist* 
Additions 
None 
lo-’ M Isoproterenol 
lo-’ M Isoproterenol 
+ 
IO-” M Practolol 
lo-’ M Isoproterenol 
+ 
10m4 M Practolol 
lo-’ M Isoproterenol 
+ 
lo-’ M Butoxamine 
lo-’ M Isoproterenol 
+ 
10W4 M Butoxamine 
CAMP? 
(pmoles/mg protein) 
7.5 Ir 0.9 
50.9 rt 7.1 
82.4 -’ 15.5 
36.6 4 7.0 
40.0 C!Z 10.2 
22.3 rt 4.1 
* Keratomed epidermal slices were preincubated at 37” 
for 20 min in buffer solution. At zero time isoproterenol 
and/or antagonist were added to the tissue in the various 
beakers. After 5 min of incubation the tissue samples were 
removed and immediately frozen in liquid nitrogen. 
i Data are expressed as the mean 2 standard error of 
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Fig. 2. Dose-response curves obtained by incubating mouse 
epidermaf tissue slices with various concentrations of iso- 
proterenol or norepineph~ne, Keratomed mouse epider- 
mal slices were preincubated for 20 min at 37” prior to the 
addition of isoproterenol (IPR) or norepinephrine (NE). 
Tissue samples were removed after 5 min of incubation and 
immediately frozen in liquid nitrogen. The procedures for 
cyclic AMP determination are given in Materials and 
Methods. Each data point represents the mean of two 
separate experiments. 
with the specific antagonists to determine the effects 
that these compounds have on the stimulation of 
cyctic AMP accumulation by IPR. IPR increased the 
levels of cyclic AMP in the tissue 6.8-fold after 5 min 
of incubation. After 10 min of incubation in the 
absence of a PDE inhibitor, this decreased to 2.9- 
fold. If the betar-antagonist was added to the tissue 
just prior to the addition of the IPR, there was an 
increase in cyclic AMP accumulation to almost lo- 
fold by the addition of lo-’ M practolol. A lo-fold 
higher concentration in the practolol levels decreased 
the initial elevation to 4.9-fold. In contrast, the 
addition of 10V5 M butoxamine to the tissue samples 
just prior to the addition of IPR resulted in a decrease 
in the levels of cyclic AMP accumulation to 5.3-fold. 
A 10-fold increase in the betaz-antagonist levels 
reduced cyclic AMP accumulation to 2.2-fold. 
The dose-response curves obtained by the addi- 
tion of a series of concentrations of IPR or norepi- 
nephrine (NE) to epidermal slices are shown in Fig. 
2. IPR is more potent in that lo-’ M IPR produced 
an 8.3-fold increase in the cyclic AMP levels in the 
epidermal slices, while 5 x 10e3M NE is required 
to produce a 6.5fold increase in the cyclic AMP 
levels. 
The results obtained with human biopsy samples 
are shown in Table 4. The addition of QH-25B (lo-’ 
M), a putative betaz-agonist, to involved psoriasis 
tissues or normal-appearing uninvolved tissues 
resulted in a 2-fold increase in the amount of cyclic 
AMP accumulated in the tissue samples compared 
to control samples. The same resuhs were obtained 
whether DNA or protein content was used as the 
data base for expressing the cyclic AMP 
concentrations. 
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Table 4. Effect of lipophi~ic &-agonist on cyclic AMP levels in human psoriatic 






Uninvolved epidermis 0.7 t 0.04 
+ W5 M QW25B 
15.2 F 0.3 
1.5 i 0.04 30.0 t I .4 
Psoriatic epidermis 0.7 t Cf. 12 10.6 ir 2.9 
+ 10-j M QH-2SB 1.4 t- 0.07 22.9 -‘- 3.3 
* Both involved (lesional) and uninvolved epidermal areas were removed with 
a keratome from each patient. The epidermal strips were cut into 3 mm squares 
and preincubated for 20 min in Krebs-Ringer bicarbonate buffer. At zero time 
QH-!25B was added to the experimental beakers containing tissue. After 3 min 
of incubation the tissue samples were removed and immediately frozen in liquid 
nitrogen. 
t Data are expressed as the mean -+ standard error of the meatl; N = three 
separate patient biopsies from involved and uninvolved areas. 
DISCUSSION 
The presence of a functional beta-adrenergi~ 
receptor in the epidermis has been demonstrated, 
as determined by an increase in the levels of cyclic 
AMP in the epidermis in response to the addition 
of IPR or epinephrine to the tissue [2, 5, 61. What 
effect such an increase in the levels of cyclic AMP 
may have with respect to the control of proliferation 
or differentiation in this tissue remains an area of 
active research. 
There are clinical data that suggest that beta 
antagonists can alter epidermal proliferation and 
differentiation [It;1st. Experimentally, the intra- 
dermal injections of propranoIo1 can induce 
increased rates of proliferation in uninvolved skin 
of psoriatic patients in comparison to control popu- 
lation [16]. The data can be interpreted to indicate 
that a blockade of the beta receptor and a possible 
decrease in cyclic AMP levels may lead to increased 
proliferation. Practolol (a betat-antagonist), when 
administered clinically, can induce psoriasiform 
lesions 117, 181 in individuaIs. These data are more 
difficult to interpret in light of the data presented in 
this paper which indicate that the receptor in the 
epidermis is beta2 in nature. The practolol effects 
may be non-specific or an indirect effect via a dermal 
component that alters the epidermal cyclic AMP 
system. 
In the isolated epidermal system employed in this 
study, the keratomed epidermal strips contained less 
than 10 per cent dermal contamination. The epider- 
ma1 strips responded to the betaz-antagonist salbu- 
tamol with an increase in the levels of cyclic AMP 
in the tissue. The increase in cyclic AMP could be 
diminished by the addition of the betaz-agonist 
butoxamine but not by the beta]-antagonist practo- 
101. Similar results were obtained with IPR, in that 
the increased levels of cyclic AMP were lessened 
with butoxamine addition, but the control levels 
were not achieved. Practolol did not decrease the 
IPR-induced increase in cyclic AMP levels; in fact. 
the cyclic AMP levels were increased. Also isopro- 
terenol is a better agonist than norepinel?hrine in 
increasing the levels of cyclic AMP in the epidermal 
slices. From previous experiments, epinephrine is 
known to be a weak agonist. These data would also 
suggest that a beta2 receptor occurs in the epidermis. 
Thus, in the isolated system relatively free of dermis, 
the receptor appears to correspond to the beta?- 
adrenergic receptor. The beta receptor may have a 
significant input into the regulation of epidermal 
proliferation and differentiation by regulating the 
levels of cyclic AMP in the tissue. 
The incubation of the patient material with the 
lipophilic beta-agonist QH-ZSS indicates that the 
compound is capable of increasing the levels of cyclic 
AMP in human tissue and may be efficacious clini- 
cally, due to its lipophilic nature. Ro 20-1724 and 
papaverine are both inhibitors of the cyclic AMP 
PDE activity that is present in the epidermis [I?)], 
in vitro, these compounds increase the levels of cyclic 
AMP in involved and uninvolved epidermal tissue 
obtained from psoriasis patients. The topical appli- 
cation of a cream containing either of these com- 
pounds, but not cream alone, improves Iesional areas 
of psoriasis [20,21]. These data support the conten- 
tion that cyclic AMP may be a critical component 
in the control of proliferation and differenti~~tion in 
epidermal basal cells. 
Additional information in the literature which 
relates to the role of cyclic AMP in the epidermis 
is obtained from tissue culture systems. In primary 
epidermal basal cell cultures obtained from neonatal 
mice, the addition of S-bromo-cyclic AMP or cholera 
toxin to the cultures results in an intracellular 
increase in the cyclic AMP levels and an increase in 
the rate of proliferation without apparent loss of 
differentiative function [22]. In the adult guinea pig 
epidermal cell cultures, the addition of dibutyryl 
cyclic AMP or isoproterenol to the cultures inhibited 
cell proliferation, as determined by DNA synthesis 
[23]. In a GZ assay system, the addition of dibutyryl 
cyclic AMP, isoproterenol, or other compounds 
capable of increasing cyclic AMP levels in human 
epidermal cultures inhibited epidermal mitosis 1241. 
Recent studies utilizing adult human primary epi- 
dermal cell cultures indicated that cyclic AMP at 
very low concentrations stimulated epidermal celi 
proliferation as measured by tritiated thym~dine 
incorporation into DNA, but at moderate or high 
teveis cyclic AMP inhibited cell proliferation 1251. 
Consequently, the beta-adrenergic system in the 
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epidermis and skin from various age groups and 7. A. M. Lands, A. Arnold, J. P. McAuliff, F. P. Luduena 
species needs to be defined more cioseiy to determine and T. G. Brown, Nature, Lond. 214, 597 (1967). 
the effects that this system may have on the main- 8. V. A. Cuilum, J. B. Farmer, D. Jack and G. P. Levy. 
tenance of normal rates of proliferation and 
Br. J. ~~ff~~UC. 35, 141 (1969). 
differentiation. 
9. Editorial Staff, Drqs I, 274 (1971). 
10. J. D. Fitzgerald, Clin. P~~urmac. Ther. 10,292 (1969). 
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